allosteric mutant IDH1/2 dual inhibitor oral, brain penetrant, completed Ph. I in HV from SBDD of prior mIDH inhibitor ACS Med. Chem. Lett., 2020, 11, 101-107 Agios Pharmaceuticals, Cambridge, MA